Overview

Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device

Status:
COMPLETED

Trial end date:
2023-10-27

Target enrollment:

Participant gender:

Summary

An Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule, Inhaler Device. Zephir inhaler robustness will be assessed by in vitro testing of the Zephir inhaler after 12 weeks of patient use

Phase:

PHASE1

Details

Lead Sponsor:

Xiromed LLC

Collaborator:

Laboratorios Liconsa

Treatments:

Hardness
Tiotropium Bromide